Lisinopril
- Generic Name
- Lisinopril
- Brand Names
- Prinivil, Qbrelis, Zestoretic, Zestril
- Drug Type
- Small Molecule
- Chemical Formula
- C21H31N3O5
- CAS Number
- 76547-98-3
- Unique Ingredient Identifier
- 7Q3P4BS2FD
- Background
Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction. Lisinopril and captopril are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system. ACEIs are commonly used as a first line therap...
- Indication
Lisinopril is indicated for the treatment of acute myocardial infarction, hypertension in patients ≥6 years, and as an adjunct therapy for heart failure. A combination product with hydrochlorothiazide is indicated for the treatment of hypertension.
- Associated Conditions
- Acute Myocardial Infarction (AMI), Cardiovascular Events, Congestive Heart Failure (CHF), Diabetic Nephropathy, Hypertension, Migraine
- Associated Therapies
- -
Renal Denervation in Patients After Acute Coronary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2013-07-17
- Last Posted Date
- 2015-09-23
- Target Recruit Count
- 80
- Registration Number
- NCT01901549
- Locations
- 🇷🇺
State Research Institute of Circulation Pathology, Novosibirsk, Russian Federation
HALT Progression of Polycystic Kidney Disease Study B
- Conditions
- Interventions
- First Posted Date
- 2013-06-25
- Last Posted Date
- 2020-04-22
- Target Recruit Count
- 486
- Registration Number
- NCT01885559
- Locations
- 🇺🇸
University of Colorado Health Sciences Center, Aurora, Colorado, United States
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Tufts University-New England Medical Center, Boston, Massachusetts, United States
Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-06-19
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 23
- Registration Number
- NCT01880528
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Risk Factor Control Before Orthopedic Surgery
- Conditions
- Interventions
- First Posted Date
- 2013-04-22
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 198
- Registration Number
- NCT01837069
- Locations
- 🇺🇸
NYU Hospital for Joint Diseases, New York, New York, United States
Bioequivalence Study of Lisinopril Tablets 40 mg Under Fed Condition
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2012-12-03
- Lead Sponsor
- IPCA Laboratories Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT01735344
- Locations
- 🇮🇳
Accutest Research Lab (I) Pvt. Ltd., Navi-Mumbai, Gujarat, India
Bioequivalence Study of Lisinopril Tablets 40 mg Under Fasting Condition
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2012-12-03
- Lead Sponsor
- IPCA Laboratories Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT01735318
- Locations
- 🇮🇳
Accutest Research Lab (I) Pvt. Ltd., Navi-Mumbai, Maharashtra, India
The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2017-09-21
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 41
- Registration Number
- NCT01691781
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension
- Conditions
- Interventions
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 17
- Registration Number
- NCT01658657
- Locations
- 🇺🇸
UNC Chapel Hill, Chapel Hill, North Carolina, United States
ACE Inhibitors to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Patients: A Pilot Study
- First Posted Date
- 2012-02-17
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 31
- Registration Number
- NCT01535235
- Locations
- 🇺🇸
San Francisco General Hospital, San Francisco, California, United States
Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH
- Conditions
- Interventions
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 70
- Registration Number
- NCT01518166
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Uppsala, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.